Mink Therapeutics, Inc. (INKT)
$0.9
Performance
- $0.88$0.95$0.90
2.21%
Downside
Day's Volatility :7.36%
Upside
5.26%
- $0.75$1.96$0.90
16.67%
Downside
52 Weeks Volatility :61.73%
Upside
54.08%
Returns
| Period | Mink Therapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 0.27% | 6.5% | 0.0% |
6 Months | 10.27% | 7.1% | 0.0% |
1 Year | -46.86% | 9.8% | 0.0% |
3 Years | -92.25% | 14.2% | -20.2% |
Highlights
Market Capitalization | 35.8M |
Book Value | - $0.58 |
Earnings Per Share (EPS) | -0.59 |
Wall Street Target Price | 8.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -111.24% |
Return On Equity TTM | -1238.98% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -20.7M |
Diluted Eps TTM | -0.59 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.4 |
EPS Estimate Next Year | -0.44 |
EPS Estimate Current Quarter | -0.15 |
EPS Estimate Next Quarter | -0.13 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 788.89%
Technicals Summary
Sell
Neutral
Buy
Mink Therapeutics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Mink Therapeutics, Inc. | 4.49% | 10.27% | -46.86% | -92.25% | -92.25% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Mink Therapeutics, Inc. | NA | NA | NA | -0.4 | -12.39 | -1.11 | NA | -0.58 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Mink Therapeutics, Inc. | Buy | $35.8M | -92.25% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Mink Therapeutics, Inc.
Decreasing Revenue
Revenue is down for the last 2 quarters, 11.70B → -11.70B (in $), with an average decrease of 200.0% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -5.45M → -3.81M (in $), with an average increase of 43.2% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 108.5%
Institutional Holdings
Vanguard Group Inc
0.59%Longbow Finance SA
0.42%Renaissance Technologies Corp
0.27%Geode Capital Management, LLC
0.23%BlackRock Inc
0.19%CapTrust Financial Advisors
0.14%
Company Information
Organization | Mink Therapeutics, Inc. |
Employees | 31 |
CEO | Dr. Garo H. Armen Ph.D. |
Industry | Services |
